Pharvaris N.V.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment and prevention of bradykinin-mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Founded in 2015 and headquartered in Zug, Switzerland, with operations in the Netherlands and the United States, the company advances deucrictibant as its lead candidate: PHVS416, an immediate-release softgel capsule for on-demand HAE attack treatment; and PHVS719, an extended-release tablet for prophylactic use. Its pipeline targets patients aged 12 and older across global markets, with pivotal Phase 3 trials conducted in 24 countries. In December 2025, Pharvaris announced positive topline results from the RAPIDe-3 Phase 3 trial of deucrictibant immediate-release capsules, meeting the primary endpoint of median time to onset of symptom relief at 1.28 hours versus over 12 hours for placebo, and achieving all 11 secondary endpoints including rapid symptom resolution; topline data from the ongoing CHAPTER-3 prophylactic trial is expected in the second half of 2026, with a U.S. New Drug Application submission planned for the first half of 2026. Earlier in July 2025, the company completed an upsized $175 million underwritten public offering of ordinary shares to fund late-stage clinical programs, U.S. commercialization efforts including sales and marketing team hiring, and general corporate purposes.
Company News
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock
Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS
5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet